On Dec. 19, 2025, Cytokinetics announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten),…
On Dec. 18, 2025, the National Aeronautics and Space Administration (NASA) announced it has opened the International Space…
On Dec. 18, 2025, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S….
On Dec. 12, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved two new oral…
On Dec. 11, 2025, USAntibiotics, the country’s only domestic manufacturer of amoxicillin (Amoxil®) and amoxicillin clavulanate (Augmentin®), announced…
On Dec. 9, 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the…
On Dec. 8, 2025, the U.S. Food and Drug Administration (FDA) approved two milestone treatments, Casgevy and Lyfgenia,…
On Dec. 5, 2025, a federal vaccine advisory committee voted on Friday to end the longstanding recommendation that…
On Dec. 5, 2025, the West Coast Health Alliance (WCHA) announced that it strongly supports that hepatitis B…
On Dec. 4, 2025, Merck Animal Health announced the U.S. Food and Drug Administration (FDA) has granted a…
On Dec. 1, 2025, the U.S. Food and Drug Administration (FDA) announced the deployment of agentic AI capabilities…
On Nov. 21, 2025, Pfizer and Astellas Pharma announced that the U.S. Food and Drug Administration (FDA) has…
On Nov. 20, 2025, the US Food and Drug Administration (FDA) has approved the first cancer drug based…
On Nov. 20, 2025, the National Institutes of Health (NIH) has canceled funding for at least 383 clinical…
On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…
On Nov. 17, 2025, Sandoz announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by…
On Nov. 13, 2025, the U.S. Food and Drug Administration (FDA) approved multiple denosumab biosimilars, enhancing market access…
On Nov. 6, 2025, Eli Lilly announced an agreement with the U.S. government to expand access to its…
On Nov. 4, 2025, the U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor,…
On Oct. 29, 2025, the U.S. Food and Drug Administration (FDA) announced it is aiming to reduce the…
On Oct. 28, 2025, Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer…
On Oct. 27, 2025, Qureator announced a major milestone, confirming a fundamental shift in drug development under the…
On Oct. 23, 2025, GSK announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf)…
On Oct. 20, 2025, Glaukos announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD…
On Oct. 17, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1…
On Oct. 16, 2025, the Food and Drug Administration (FDA) announced the first round of experimental drugs that…
On Oct. 13, 2025, the U.S. Food and Drug Administration (FDA) announces it has cleared the Elecsys pTau181…
On Oct. 9, 2025, Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug…
On Oct. 9, 2025, Celltrion announced announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar…
On Oct. 3, 2025, the U.S. Food and Drug Administration (FDA) announced a new pilot prioritization program for…